Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1387)	8/24/2005 10:14:09 AM
From: Jibacoa	Respond to of 3722

NEOL Opened with a good upgap today after it announced that the FDA has approved its SPA, which includes an analysis of data from its PIII of cintredekin besudotox for the treatment of GBM. They expect full enrollment in the PIII by the end of the year, and an interim "Efficacy Analysis" is projected to occur in 2ndQ of 2006. The stock is up 8% and volume has expanded to 927,209 it traded at 13.85 at 9.30AM, above its December H of 13.59, making a 52wks. H The stock is now trading at 13.24, and is not showing plans of closing its upgap in spite of the poor cooperation from the market.<g> bigcharts.marketwatch.com It seems that with its current momentum the stock could get to the 16 level. (The analysts' consensus is around 17)<g> bigcharts.marketwatch.com Bernard